🛒Order Your Prescription Meds Online With Ease🛒

💊 Get UPTO 25% Discount on All Medicines

🎟️ Use Coupon Code & Save More!

 

Introduction

Adipex is one of the most recognized brand names in prescription weight-loss medication and, at the same time, one of the most narrowly indicated. Its active ingredient is phentermine hydrochloride, a sympathomimetic amine with pharmacologic activity similar to amphetamine . It has been available in the United States since 1959 .

For patients with obesity for whom diet, exercise, and behavioral changes alone are insufficient, Adipex can provide short-term support as an adjunct to a comprehensive weight-management plan. It is also a Schedule IV controlled substance with a well-documented set of properties—cardiovascular effects, tolerance to the anorectic effect, contraindications in specific populations, and interaction risks—that make how it is prescribed and taken genuinely important.

This guide covers Adipex in full: what it is, its formulations, its approved use, how it works, its effects, its contraindications, its legal classification, and what appropriate medical access and monitoring look like.

What Is Adipex?

Adipex is a brand name for phentermine hydrochloride. It is a sympathomimetic amine anorectic—a medication that reduces appetite through central nervous system action .

Available Formulations

Adipex-P tablets — 37.5 mg phentermine hydrochloride, equivalent to 30 mg phentermine base . The tablet is white, oblong, and scored, debossed with "ADIPEX-P" and "9"-"9" .

Adipex-P capsules — also available as 37.5 mg phentermine hydrochloride .

Phentermine is also marketed under other brand names including Lomaira, Fastin, and Ionamin, and in generic form . The combination of phentermine and topiramate is sold as Qsymia .

A Note on the Active Ingredient

Phentermine hydrochloride is a white, odorless, hygroscopic, crystalline powder. It is chemically related to amphetamine, and this relationship underlies both its therapeutic effect and its abuse potential .

Approved Medical Use

Adipex has a specific and narrow approved indication.

Short-Term Adjunct for Exogenous Obesity

Adipex-P is indicated as a short-term (a few weeks) adjunct in a regimen of weight reduction based on exercise, behavioral modification, and caloric restriction in the management of exogenous obesity for patients with an initial body mass index (BMI) of:

• ≥30 kg/m², or

• ≥27 kg/m² in the presence of other risk factors (e.g., controlled hypertension, diabetes, hyperlipidemia)

The labeling is explicit that Adipex-P is indicated only as short-term monotherapy for the management of exogenous obesity. Co-administration with other drug products for weight loss is not recommended, as the safety and efficacy of combination therapy have not been established .

Dosing

The usual adult dose is one tablet (37.5 mg) daily, administered before breakfast or 1 to 2 hours after breakfast. For some patients, half a tablet (18.75 mg) daily may be adequate. Late evening medication should be avoided because of the possibility of resulting insomnia .

For patients with severe renal impairment (eGFR 15 to 29 mL/min/1.73 m²), the dosage should be limited to 15 mg daily. Adipex-P should be avoided in patients with eGFR less than 15 mL/min/1.73 m² or end-stage renal disease requiring dialysis .

What Adipex Is Not Approved For

• Pediatric patients ≤16 years of age — safety and effectiveness have not been established

• Long-term use — the indication is explicitly short-term

• Combination with other weight-loss drugs — not recommended

• Use without a prescription — Adipex is a Schedule IV controlled substance

How Adipex Works

Phentermine is a sympathomimetic amine with pharmacologic activity similar to amphetamine, the prototype drug of this class used in obesity . Drugs of this class are commonly known as "anorectics" or "anorexigenics."

It has not been established that the primary action of phentermine in treating obesity is appetite suppression alone, as other central nervous system actions or metabolic effects may also be involved .

Pharmacokinetics

Following administration, phentermine reaches peak concentrations after 3.0 to 4.4 hours. Cumulative urinary excretion under uncontrolled urinary pH conditions was 62% to 85%. Systemic exposure may increase up to 91% in severe renal impairment, 45% in moderate, and 22% in mild .

Clinical Trial Data

In relatively short-term clinical trials, adult obese subjects treated with anorectic drugs lost more weight on average than those treated with placebo and diet. However, the labeling notes that the magnitude of increased weight loss over placebo is only a fraction of a pound a week, and the rate of weight loss is greatest in the first weeks of therapy for both drug and placebo subjects .

Tolerance, Abuse, and Dependence

Tolerance to the Anorectic Effect

Tolerance to the anorectic effect usually develops within a few weeks. If this occurs, Adipex-P should be discontinued. The recommended dose should not be exceeded .

This is a defining clinical feature of Adipex: it is not a medication intended for indefinite use, and the labeling anticipates that its effect will diminish.

Abuse and Dependence

Adipex-P is related chemically and pharmacologically to amphetamine and other stimulant drugs that have been extensively abused. The possibility of abuse should be kept in mind when evaluating the desirability of including it as part of a weight-reduction program . The labeling directs that the least amount feasible should be prescribed or dispensed at one time to minimize the possibility of overdosage .

Withdrawal

The labeling lists "withdrawal effects following prolonged high dosage administration" among the adverse reactions .

Cardiovascular and Other Serious Risks

Primary Pulmonary Hypertension

Rare cases of primary pulmonary hypertension (PPH) have been reported in patients receiving a combination of phentermine with fenfluramine or dexfenfluramine. The possibility of an association between PPH and the use of Adipex-P alone cannot be ruled out; there have been rare cases of PPH in patients who reportedly have taken phentermine alone. The initial symptom is usually dyspnea. Adipex-P should be discontinued in case of new, unexplained symptoms of dyspnea, angina pectoris, syncope, or lower extremity edema .

Valvular Heart Disease

Serious regurgitant cardiac valvular disease has been reported in otherwise healthy persons who had taken a combination of phentermine with fenfluramine or dexfenfluramine. The possible role of phentermine alone in the etiology of these valvulopathies has not been established, and the possibility of an association cannot be ruled out .

Blood Pressure

Adipex-P should be used with caution in patients with even mild hypertension, due to the risk of increase in blood pressure .

Impairment of Hazardous Tasks

Adipex-P may impair the ability to engage in potentially hazardous activities such as operating machinery or driving a motor vehicle .

Diabetic Patients

A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients with diabetes mellitus .

Overdosage

Management of acute phentermine intoxication is largely symptomatic and includes lavage and sedation with a barbiturate. Acidification of the urine increases phentermine excretion .

Common Side Effects

The following adverse reactions have been identified with phentermine :

Cardiovascular: Palpitation, tachycardia, elevation of blood pressure, precordial pain, arrhythmia. One published report described T-wave changes in the ECG of a healthy young male after ingestion of phentermine hydrochloride.

Central Nervous System: Overstimulation, restlessness, dizziness, insomnia, euphoria, dysphoria, tremor, headache, rarely psychotic episodes at recommended doses.

Gastrointestinal: Dryness of the mouth, unpleasant taste, diarrhea, constipation, other gastrointestinal disturbances.

Allergic: Urticaria.

Endocrine: Impotence, changes in libido.

Any persistent or distressing effect should be reported to the prescriber.

Contraindications

Adipex-P is contraindicated in the following circumstances :

• History of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension)

• During or within 14 days following administration of monoamine oxidase inhibitors (MAOIs) — risk of hypertensive crisis

• Hyperthyroidism

• Glaucoma

• Agitated states

• History of drug abuse

• Pregnancy — weight loss offers no potential benefit to a pregnant woman and may result in fetal harm

• Nursing — it is not known if phentermine is excreted in human milk, but other amphetamines are present in human milk

• Known hypersensitivity or idiosyncrasy to sympathomimetic amines

Drug Interactions

Adipex-P interacts with several medications and substances. Anyone taking it should disclose all medications, supplements, and recreational substances to their prescriber and pharmacist.

Notable interactions include :

• MAOIs — Risk of hypertensive crisis. Contraindicated during or within 14 days of MAOI administration.

• Alcohol — Concomitant use may result in an adverse drug reaction; consider potential interaction.

• Insulin and oral hypoglycemics — Requirements may be altered.

• Adrenergic neuron blocking drugs — Adipex-P may decrease the hypotensive effect of these drugs.

Additional considerations from clinical sources include interactions with other stimulants (increased risk of high blood pressure, fast heartbeat, anxiety), diabetes medications (increased risk of low blood sugar), and blood pressure medications (Adipex-P may make them less effective) .

This is not an exhaustive list. A pharmacist consultation is advisable before starting any new medication while taking Adipex.

What Appropriate Medical Access and Monitoring Look Like

Step 1: Proper Clinical Evaluation

Adipex-P is indicated for patients with exogenous obesity and a BMI of ≥30 kg/m², or ≥27 kg/m² with other risk factors . A clinician can assess whether Adipex is appropriate and whether a comprehensive weight-management plan is in place.

Step 2: A Valid Prescription

Adipex is a Schedule IV controlled substance . This means it requires a prescription from a licensed prescriber with a valid DEA registration. Schedule IV status permits refills in some circumstances, subject to state law and prescriber discretion, but still requires an established prescriber-patient relationship.

Step 3: Dispensing at a Licensed Pharmacy

Prescriptions are dispensed by a licensed pharmacy. Pharmacists verify prescriptions and may check prescription drug monitoring programs.

Step 4: Short-Term Use and Monitoring

The labeling is explicit that Adipex is for short-term use. Prescribers should monitor:

• Weight loss response and whether the medication is providing benefit

• Blood pressure, particularly in patients with hypertension

• Development of tolerance to the anorectic effect — if it occurs, Adipex-P should be discontinued

• Signs of abuse or misuse

• Cardiovascular symptoms (dyspnea, angina, syncope, lower extremity edema)

Step 5: Discontinuation

If tolerance develops or the short-term treatment course is complete, Adipex should be discontinued. Individual patient circumstances should be discussed with the prescriber.

Frequently Asked Questions

What is Adipex used for?

Adipex is indicated as a short-term (a few weeks) adjunct in a weight-reduction regimen for patients with exogenous obesity and a BMI of ≥30 kg/m², or ≥27 kg/m² with other risk factors .

Is Adipex a controlled substance?

Yes. Adipex is a Schedule IV controlled substance .

How long can Adipex be taken?

The labeling specifies short-term use—a few weeks. Tolerance to the anorectic effect usually develops within a few weeks, and if it occurs, Adipex-P should be discontinued .

Can Adipex be taken with other weight-loss medications?

No. Adipex-P is indicated only as short-term monotherapy. Co-administration with other drug products for weight loss is not recommended because safety and efficacy of combination therapy have not been established .

Who should not take Adipex?

Adipex is contraindicated in patients with a history of cardiovascular disease, hyperthyroidism, glaucoma, agitated states, history of drug abuse, during or within 14 days of MAOI use, and in pregnancy and nursing .

What are the common side effects?

Palpitation, tachycardia, elevation of blood pressure, restlessness, dizziness, insomnia, dry mouth, unpleasant taste, diarrhea, constipation, and changes in libido are among the reported effects .

What is the most serious risk?

Rare cases of primary pulmonary hypertension and serious regurgitant cardiac valvular disease have been reported. Adipex-P should be discontinued if new, unexplained symptoms of dyspnea, angina, syncope, or lower extremity edema occur .

What should I do if I experience serious effects?

Seek medical attention for new or worsening shortness of breath, chest pain, fainting, swelling of the legs, or signs of an allergic reaction.

Conclusion

Adipex is an effective short-term adjunct for weight reduction in patients with obesity when used alongside exercise, behavioral modification, and caloric restriction. It is also a Schedule IV controlled substance related to amphetamine, with a defined set of cardiovascular risks, contraindications, and a predictable development of tolerance to its anorectic effect. The labeling is unambiguous that it is for short-term monotherapy, not indefinite use or combination with other weight-loss drugs.